Download MendeleyAn Orally Available Halothiazole Glycomimetic as a Cancer-Targeting Dual Galectin-1 and Galectin-3 Inhibitor.
Zetterberg, F.R., Peterson, K., Nilsson, U.J., Diehl, C., Hakansson, M., Kahl-Knutson, B., MacKinnon, A.C., Klein, H., Leffler, H., Roper, J.A., Slack, R.J., Wachenfeldt, H.V., Pedersen, A.(2026) J Med Chem 69: 10494-10514
- PubMed: 42052938 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.5c03703
- Primary Citation Related Structures:
8RDC, 8RXM - PubMed Abstract:
Inhibition of several of the 10 hallmarks of cancer (Hanahan and Weinberg) would result in a broader and more durable treatment compared to current single or combination drug treatments. Galectin-1 and galectin-3 have been proposed to together be involved in all 10 hallmarks, suggesting that development of a combined galectin-1/3 inhibitor would be beneficial. Specificity toward galectin-1 or -3 can be modulated using different aryl moieties in 3-(aryl)triazolyl-galactopyranoside derivatives. By combining these findings, a new class of 3-(halothiazolyl)triazolyl derivatives with high affinity for both human galectin-1 and -3 were discovered and optimized with respect to SAR and in vitro ADME parameters, resulting in GB1841 ( K d galectin-1/-3 0.027/0.14 μM). Both selective and dual inhibition of galectin-1 and galectin-3 significantly reduces the growth of LL/2 lung cancer cells in a syngeneic mouse model, supporting further development of GB1841 as a dual inhibitor of galectin-1 and galectin-3.
- Galecto Biotech AB, Sahlgrenska Science Park, Medicinaregatan 8 A, Gothenburg SE-413 46, Sweden.
Organizational Affiliation:
